Long-acting somatostatin analogues in the treatment of children with congenital hyperinsulinism. Literature review
- Authors: Savkina A.R.1, Kareva M.A2, Melikyan M.A2
-
Affiliations:
- Pirogov Russian National Research Medical University
- National Medical Research Center for Endocrinology
- Issue: Vol 27, No 9 (2020)
- Pages: 38-41
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312782
- DOI: https://doi.org/10.18565/pharmateca.2020.9.38-41
- ID: 312782
Cite item
Open Access
Access granted
Abstract
Congenital hyperinsulinism (CHI) is a hereditary disease characterized by inadequate insulin hypersecretion by pancreatic ß-cells, leading to severe hypoglycemia. One of the most common causes of CHI is the inactivation mutation of the ABCC8 and KCNJ11 genes. The first-line therapy for CHI is diazoxide. However, there are forms resistant to this treatment. In such cases, somatostatin analogues (SA) are used. For this article, an analysis of relevant literature in the field of treatment of CHI was carried out. Clinical observations of foreign authors on the successful use of long-acting SA in CHI are presented. It is concluded that SA remain the leading drugs for the treatment of diazoxide-resistant forms of CHI. The scientific community gives particular preference to long-acting forms of SA proving their effectiveness and safety in studies.
Full Text
About the authors
Anastasiya R. Savkina
Pirogov Russian National Research Medical University
Email: ifeel1996@mail.ru
sixth-year student of the faculty of pediatrics 1, Ostrovityanova str., Moscow 117997, Russian Federation
M. A Kareva
National Medical Research Center for EndocrinologyMoscow, Russia
M. A Melikyan
National Medical Research Center for EndocrinologyMoscow, Russia
References
- De Cosio A.P., Thornton P. Current and Emerging Agents for the Treatment of Hypoglycemia in Patients with Congenital Hyperinsulinism. Pediatric Drugs. 2019;21:123-36. doi: 10.1007/s40272-019-00334-w.
- Banerjee I., Salomon-Estebanez M., Shah P., et al. Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia. Diabetic Medicine. 2019;36:9-21. doi: 10.1111/dme.13823.
- Меликян М.А. Федеральные клинические рекомендации по диагностике, лечению и ведению детей и подростков с врожденным гиперинсулинизмом. Проблемы эндокринологии. 2014;2:31-41 doi: 10.14341/probl201460231-41.
- Щедеркина И.О., Меликян М.А., Заваденко А.Н. и др. Неврологические пароксизмальные нарушения у детей с гипогликемией на фоне врожденного гиперинсулинизма: полиморфизм клинических проявлений. Эпилепсия и пароксизмальные состояния. 2015;2:49-58. doi: 10.17749/2077-8333.2015.7.2.049-058.
- Galcheva S., Al-Khawaga S., Hussain K. Diagnosis and management of hyperinsulinaemic hypoglycaemia. Best Pract Res Clin Endocrinol Metab. 2018;32(4):551-73. Doi: 10.1016/j. beem.2018.05.014.
- Van der Steen I., van Albada M. E., Mohnike K., et al. A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism. Horm Res Paediatr. 2017;89(2):82-9.doi: 10.1159/000485184.
- Pan S., Zhang M., Li. Y. Experience of Octreotide Therapy for Hyperinsulinemic Hypoglycemia in Neonates Born Small for Gestational Age: A Case Series. Horm Res Paediatr. 2015;84(6):383-87. doi: 10.1159/000441108.
- Vora S., Chandran S., Rajadurai V.S., Hussain K. Hyperinsulinemic hypoglycemia in infancy: Current concepts in diagnosis and management. Indian Pediatr. 2015;52(12):1051-59. doi: 10.1007/s13312-015-0772-1.
- Demirbilek H., Rahman S.A., Buyukyilmaz G.G., et al. Diagnosis and treatment of hyperinsulinaemic hypoglycaemia and its implications for paediatric endocrinology. Int J Pediatr Endocrinol. 2017;2017:9. doi: 10.1186/s13633-017-0048-8.
- Yorifuji T., Kawakita R., Hosokawa Y., et al. Efficacy and safety of long-term, continuous subcutaneous octreotide infusion for patients with different subtypes of KATP-channel hyperinsulinism. Clin Endocrinol. 2013;78(6):891-97. doi: 10.1111/cen.12075.
- Hosokawa Y., Kawakita R., Yokoya S., Ogata et al. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry. Endocrine J. 2017;64(9):867-80. doi: 10.1507/endocrj. ej17-0024.
- Kühnen P., Marquard J., Ernert A., et al. Long-Term Lanreotide Treatment in Six Patients with Congenital Hyperinsulinism. Horm Res Paediatr. 2012;78(2):106-12. doi: 10.1159/000341525.
- Modan-Moses D., Koren I., Mazor-Aronovitch K., et al. Treatment of Congenital Hyperinsulinism with Lanreotide Acetate (Somatuline Autogel). J Clin Endocrinol Metab. 2011;96(8):2312-17. doi: 10.1210/jc.2011-0605.
- Corda H., Kummer S., Welters A., et al. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism. Orphanet J Rare Dis. 2017;12(1):108. doi: 10.1186/s13023-017-0653-x.
- McMahon A.W., Wharton G.T., Thornton P., et al. Octreotide use and safety in infants with hyperinsulinism. Pharmacoepidemiol Drug Saf. 2016;26(1):26-31. doi: 10.1002/pds.4144.
- Shah P., Rahman S. A., McElroy S., et al. Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact. Horm Res Paediatr. 2015;84(5):355-60. doi: 10.1159/000439131.
- Hawkes C.P., Adzick N.S., Palladino A.A., et al. Late Presentation of Fulminant Necrotizing Enterocolitis in a Child with Hyperinsulinism on Octreotide Therapy. Horm Res Paediatr. 2016;86(2):131-36. doi: 10.1159/000443959.
- Laje P., Halaby L., Adzick N.S., et al. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes. 2010;11 (2): 142-47. doi: 10.1111/j.1399-5448.2009.00547.x.
Supplementary files
